# iBio (stock symbol: IBIO) Logo in transparent PNG format

## iBio Logo large

### iBio Logo large Download PNG (26.89 KB)

![iBio Logo large Download PNG (26.89 KB)](/img/orig/IBIO_BIG-6f9724bc.png)

## iBio Logo icon format

### iBio Logo icon format Download PNG (36.12 KB)

![iBio Logo icon format Download PNG (36.12 KB)](/img/orig/IBIO-c9a2c3f4.png)

## About iBio

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202 , which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties; and offers a range of process development, manufacturing, and bio analytic services. iBio, Inc. has a license agreement with University of Pittsburgh; a non-exclusive agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with RubrYc. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

1. Website domain: ibioinc.com
2. Employees: 105
3. Marketcap: $13.35 Million USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
